Don’t market stem-cell products ahead of proof

The controversy over an unproven stem-cell therapy in Italy highlights the dangers of doing translational medicine in reverse, argues Paolo Bianco.

Nature 499 255 doi: 10.1038/499255a

Powered by WPeMatico

Share
This entry was posted in Science. Bookmark the permalink.

Comments are closed.